EDIGENE INC.

In News

Clinical Update: EdiGene Enrols First Patient in Phase 1 Trial for Transfusion-Dependent Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Sep 15, 2021

EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies - Business Wire

Business Wire - Nov 07, 2022

EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies - bioinformant.com

bioinformant.com - Feb 21, 2022

Trials to watch: CRISPR pipeline accelerates after milestone Casgevy approval - Clinical Trials Arena

Clinical Trials Arena - Jan 17, 2024

EdiGene, First in China Permitted to Clinical Trial Gene-Editing Tech, Banks USD61.7 Million - Yicai Global

Yicai Global - May 13, 2025

Gene-edited immune cells show promise for universal 'off-the-shelf' cancer therapy - Medical Xpress

Medical Xpress - Sep 08, 2025

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia - Business Wire

Business Wire - Nov 18, 2022

Clinical Roundup: Gene-Edited Therapies for Beta Thalassemia - CRISPR Medicine News

CRISPR Medicine News - Jul 26, 2023

Weekly Top 5 in China (0210-0216) - geneonline.com

geneonline.com - Feb 18, 2019

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment